148 related articles for article (PubMed ID: 38006670)
1. Racialized and beneficiary inequities in medication to treat opioid use disorder receipt within the US Military Health System.
Lance Tippit T; O'Connell MA; Costantino RC; Scott-Richardson M; Peters S; Pakieser J; Tilley LC; Highland KB
Drug Alcohol Depend; 2023 Dec; 253():111025. PubMed ID: 38006670
[TBL] [Abstract][Full Text] [Related]
2. Use of Medication for Opioid Use Disorder Among US Adolescents and Adults With Need for Opioid Treatment, 2019.
Mauro PM; Gutkind S; Annunziato EM; Samples H
JAMA Netw Open; 2022 Mar; 5(3):e223821. PubMed ID: 35319762
[TBL] [Abstract][Full Text] [Related]
3. Explaining Racial-ethnic Disparities in the Receipt of Medication for Opioid Use Disorder during Pregnancy.
Gao YA; Drake C; Krans EE; Chen Q; Jarlenski MP
J Addict Med; 2022 Nov-Dec 01; 16(6):e356-e365. PubMed ID: 35245918
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with receipt of medication for opioid use disorder among pregnant individuals entering treatment programs in the U.S.
Curran L; Manuel J
Int J Drug Policy; 2024 Apr; 126():104342. PubMed ID: 38479161
[TBL] [Abstract][Full Text] [Related]
5. Duration of medication for opioid use disorder during pregnancy and postpartum by race/ethnicity: Results from 6 state Medicaid programs.
Austin AE; Durrance CP; Ahrens KA; Chen Q; Hammerslag L; McDuffie MJ; Talbert J; Lanier P; Donohue JM; Jarlenski M
Drug Alcohol Depend; 2023 Jun; 247():109868. PubMed ID: 37058829
[TBL] [Abstract][Full Text] [Related]
6. Disparities in receipt of medications for opioid use disorder among pregnant women.
Henkhaus LE; Buntin MB; Henderson SC; Lai P; Patrick SW
Subst Abus; 2022; 43(1):508-513. PubMed ID: 34270396
[No Abstract] [Full Text] [Related]
7. Accessibility to Medication for Opioid Use Disorder After Interventions to Improve Prescribing Among Nonaddiction Clinics in the US Veterans Health Care System.
Hawkins EJ; Malte CA; Gordon AJ; Williams EC; Hagedorn HJ; Drexler K; Blanchard BE; Burden JL; Knoeppel J; Danner AN; Lott A; Liberto JG; Saxon AJ
JAMA Netw Open; 2021 Dec; 4(12):e2137238. PubMed ID: 34870679
[TBL] [Abstract][Full Text] [Related]
8. Receipt of Telehealth Services, Receipt and Retention of Medications for Opioid Use Disorder, and Medically Treated Overdose Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Hodges K; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2022 Oct; 79(10):981-992. PubMed ID: 36044198
[TBL] [Abstract][Full Text] [Related]
9. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: Expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities.
Gordon AJ; Drexler K; Hawkins EJ; Burden J; Codell NK; Mhatre-Owens A; Dungan MT; Hagedorn H
Subst Abus; 2020; 41(3):275-282. PubMed ID: 32697170
[TBL] [Abstract][Full Text] [Related]
10. Association of Receipt of Opioid Use Disorder-Related Telehealth Services and Medications for Opioid Use Disorder With Fatal Drug Overdoses Among Medicare Beneficiaries Before and During the COVID-19 Pandemic.
Jones CM; Shoff C; Blanco C; Losby JL; Ling SM; Compton WM
JAMA Psychiatry; 2023 May; 80(5):508-514. PubMed ID: 36988913
[TBL] [Abstract][Full Text] [Related]
11. Access to Medications for Opioid Use Disorder in Rural Versus Urban Veterans Health Administration Facilities.
Wyse JJ; Shull S; Lindner S; Morasco BJ; Gordon AJ; Carlson KF; Korthuis PT; Ono SS; Liberto JG; Lovejoy TI
J Gen Intern Med; 2023 Jun; 38(8):1871-1876. PubMed ID: 36690913
[TBL] [Abstract][Full Text] [Related]
12. Availability of Medications for the Treatment of Opioid Use Disorder Among Pregnant and Postpartum Individuals in US Jails.
Sufrin C; Kramer CT; Terplan M; Fiscella K; Olson S; Voegtline K; Latkin C
JAMA Netw Open; 2022 Jan; 5(1):e2144369. PubMed ID: 35050354
[TBL] [Abstract][Full Text] [Related]
13. Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.
Miles J; Treitler P; Hermida R; Nyaku AN; Simon K; Gupta S; Crystal S; Samples H
Drug Alcohol Depend; 2023 Nov; 252():110963. PubMed ID: 37748421
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a claim-based provider-level measurement of use of medications to treat opioid use disorder.
Dowd WN; Barch DH; Seibert JH; Mark TL
J Subst Abuse Treat; 2022 Sep; 140():108824. PubMed ID: 35780730
[TBL] [Abstract][Full Text] [Related]
15. The impact of military sexual trauma and gender on receipt of evidence-based medication treatment among veterans with opioid use disorder.
Beckman KL; Williams EC; Hebert P; Hawkins EJ; Littman AJ; Lehavot K
J Subst Abuse Treat; 2022 Aug; 139():108775. PubMed ID: 35317959
[TBL] [Abstract][Full Text] [Related]
16. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Racial and Ethnic Disparities in the Use of Medication to Treat Opioid Use Disorder Among Pregnant Women in Massachusetts.
Schiff DM; Nielsen T; Hoeppner BB; Terplan M; Hansen H; Bernson D; Diop H; Bharel M; Krans EE; Selk S; Kelly JF; Wilens TE; Taveras EM
JAMA Netw Open; 2020 May; 3(5):e205734. PubMed ID: 32453384
[TBL] [Abstract][Full Text] [Related]
18. Provider-directed marketing may increase prescribing of medications for opioid use disorder.
Nguyen T; Andraka-Christou B; Simon K; Bradford WD
J Subst Abuse Treat; 2019 Sep; 104():104-115. PubMed ID: 31370974
[TBL] [Abstract][Full Text] [Related]
19. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
Krawczyk N; Rivera BD; Jent V; Keyes KM; Jones CM; Cerdá M
Int J Drug Policy; 2022 Dec; 110():103786. PubMed ID: 35934583
[TBL] [Abstract][Full Text] [Related]
20. The impact of COVID-19 and rapid policy exemptions expanding on access to medication for opioid use disorder (MOUD): A nationwide Veterans Health Administration cohort study.
Livingston NA; Davenport M; Head M; Henke R; LeBeau LS; Gibson TB; Banducci AN; Sarpong A; Jayanthi S; Roth C; Camacho-Cook J; Meng F; Hyde J; Mulvaney-Day N; White M; Chen DC; Stein MD; Weisberg R
Drug Alcohol Depend; 2022 Dec; 241():109678. PubMed ID: 36368167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
